High efficacy of concomitant treatment of undifferentiated (anaplastic) thyroid cancer with radiation and docetaxel

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 9, 2010, Pages

  Troch, Marlene ^a   Koperek, Oskar ^a   Scheuba, Christian ^a   Dieckmann, Karin ^a   Hoffmann, Martha ^a   Niederle, Bruno ^a   Raderer, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; ESOPHAGITIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LEUKOPENIA; LUNG METASTASIS; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RADIATION DERMATITIS; RADIATION DOSE; RADIATION INJURY; RETROSPECTIVE STUDY; STOMATITIS; THYROID CANCER; TREATMENT RESPONSE; URINARY TRACT INFECTION; ADJUVANT CHEMOTHERAPY; CARCINOMA; CELL DIFFERENTIATION; EVALUATION STUDY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; RADIATION DOSE FRACTIONATION; SURVIVAL; THYROID NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL DIFFERENTIATION; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 77956602750     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2827     Document Type: Article

References (20)

1. Gilliland FD, Hunt WC, Morris DM, Key CR 1997 Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564-573
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648
3. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A 2005 Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103:1330-1335
4. Ain KB 1998 Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 8:715-726
5. Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC 2009 Multimodality treatment for anaplastic thyroid carcinoma. Treatment outcome in 75 patients. Radiother Oncol 92:100-104
6. Passler C, Scheuba C, Prager G, Kaserer K, Flores JA, Vierhapper H, Niederle B 1999 Anaplastic (undifferentiated) thyroid carcinoma (ATC). Langenbecks Arch Surg 384:284-293
7. Are C, Shaha AR 2006 Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 13:453-464
8. Lang BH, Lo CY 2007 Surgical options in undifferentiated thyroid carcinoma. World J Surg 31:969-977
9. Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J 2006 Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 107:1786-1792
10. Mitchell G, Huddart R, Harmer C 1999 Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 50:33-38
11. Hoskin PJ, Harmer C 1987 Chemotherapy for thyroid cancer. Radiother Oncol 10:187-194
12. De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, Casara D, Zorat P, Fiorentino MV 1991 Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14:475-480
13. Asakawa H, Kobayashi T, Komoike Y, Maruyama H, Nakano Y, Tamaki Y, Matsuzawa Y, Monden M 1997 Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res 17:2757-2762 (Pubitemid 27352683)
14. Yau T, Lo CY, Epstein RJ, Lam AK, Wan KY, Lang BH 2008 Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol 15:2500-2505
15. Chen J, Tward JD, Shrieve DC, Hitchcock YJ 2008 Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol 31:460-464
16. Dandekar P, Harmer C, Barbachano Y, Rhys-Evans P, Harrington K, Nutting C, Newbold K 2009 Hyperfractionated accelerated radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys 74:518-521
17. Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H, Grimelius L, Lundell G, Wallin G 1998 Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year-period. World J Surg 22:725-730
18. Lam KY, Lo CY, Chan KW, Wan KY 2000 Insular and anaplastic carcinoma of the thyroid: a 45 year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg 231:329-338
19. DeLellis RA, Llooyd RV, Heitz PH, Eng C 2004 WHO classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon, France: IARC Press
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247